Global Mild Cognitive Impairment Market Research Report By Disease Type, By Age, By Indication, By Treatment, And By Region (North America, Europe, Asia-Pacific, And Rest Of The World)

Description

List of Tables

Global Mild Cognitive Impairment Market Research Report By Disease Type (Amnestic MCI and Non-Amnestic MCI), By Age (Child, Adult, Geriatric), By Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, and Others) By Treatment (Medication (Cholinesterase Inhibitors, Benzodiazepines, Glutamate Inhibitors, Antihistamines, Mao Inhibitors, Proton Pump Inhibitors, and Others), Therapy (Cognitive Stimulation Therapy, Cognitive Behavioural Therapy (CBT)), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World - Forecast Till 2032

Market Overview

The market size for mild cognitive impairment was estimated to be USD 1.94 billion in 2023. The global mild cognitive impairment industry is expected to expand from USD 2.05 billion in 2024 to USD 3.25 billion by 2032, with a compound annual growth rate (CAGR) of 5.95% during the forecast period (2024-2032).

The growing prevalence of mild cognitive impairment around the world, as well as increased awareness of mild cognitive impairment, are the primary drivers of the Mild Cognitive Impairment Market. However, polypharmacy and controlling comorbidities complicate treatment options, which is projected to slow worldwide market growth. Nonetheless, technological developments in the early diagnosis of MCI around the world are expected to provide profitable market prospects. The rising global prevalence of moderate cognitive impairment (MCI) is a primary driver of the global MCI treatment industry.

Marketing Segmentation

Mild Cognitive Impairment Market Segmentation by Disease Type, Amnestic MCI, and Non-Amnestic MCI.

The mild cognitive impairment market segmentation by age comprises child, adult, and geriatric.

The Mild Cognitive Impairment Market has been classified according to indication: Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others.

The Mild Cognitive Impairment Market has been divided into two segments: medicine and therapy.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American mild cognitive impairment market had the greatest market share of 42.60% in 2022 and is expected to reach roughly USD 01.31 billion by 2032, growing at a 4.97% CAGR over the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 6.91% over the forecast period. The North American mild cognitive impairment market is expected to increase steadily in the future. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.

Europe's mild cognitive impairment market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increased burden of mild cognitive impairment. Furthermore, the German mild cognitive impairment market is expected to have the biggest market share, with the UK mild cognitive impairment market forecast to be the fastest expanding market in Europe.

The Asia-Pacific mild cognitive impairment market is predicted to develop the fastest from 2024 to 2032, owing to a large patient population, an increasing number of mild cognitive cases, and favorable regulatory regulations. Furthermore, prominent companies in the mild cognitive impairment market are aggressively expanding into this region, propelling the regional market forward. Furthermore, China's mild cognitive impairment market had the greatest market share, while India's mild cognitive impairment market is expected to be the fastest expanding in the Asia-Pacific region.

Major Players

Key players in the mild cognitive impairment market include Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd. (Japan), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), and Taj Pharmaceuticals Limited (India).

Product Code: MRFR/HC/9432-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Increasing burden of Mild cognitive impairment across the globe
- 4.2.2 Rising awareness associated with mild cognitive impairment
4.3 RESTRAINTS
- 4.3.1 Polypharmacy and managing comorbidities complicate treatment strategies
4.4 OPPORTUNITY
- 4.4.1 Technological advancements for early diagnosis of MCI

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL MILD COGNITIVE IMPAIRMENT MARKET

6 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY DISEASE TYPE

6.1 OVERVIEW
6.2 AMNESTIC MCI
6.3 NON-AMNESTIC MCI

7 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY AGE

7.1 OVERVIEW
7.2 CHILD
7.3 ADULT
7.4 GERIATRIC

8 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY INDICATION

8.1 OVERVIEW
8.2 LEWY BODY DEMENTIA
8.3 PARKINSON'S DISEASE DEMENTIA
8.4 ALZHEIMER'S DISEASE
8.5 VASCULAR DEMENTIA
8.6 OTHERS

9 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY TREATMENT

9.1 OVERVIEW
9.2 MEDICATION
- 9.2.1 Cholinesterase Inhibitors
- 9.2.2 Benzodiazepines
- 9.2.3 Glutamate Inhibitors
- 9.2.4 Antihistamines
- 9.2.5 Mao Inhibitors
- 9.2.6 Proton Pump Inhibitors
- 9.2.7 Others
9.3 THERAPY
- 9.3.1 Cognitive Stimulation Therapy
- 9.3.2 Cognitive Behavioural Therapy (CBT)

10 GLOBAL MILD COGNITIVE IMPAIRMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 us
- 10.2.2 canada
10.3 EUROPE
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 UK
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 South Korea
- 10.4.5 AUSTRALIA
- 10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
- 10.5.1 Middle East & Africa
- 10.5.2 Latin America

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 product launch / Product approval

12 COMPANY PROFILES

12.1 JOHNSON & JOHNSON SERVICES, INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 productS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 PFIZER INC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 productS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 NOVARTIS AG
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 productS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 ABBVIE INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 BIOGEN
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 EISAI CO., LTD.
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 AUROBINDO PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 TAJ PHARMACEUTICALS LTD.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 DATA CITATIONS